000041821 000__ 02338cam\a22002535i\4500
000041821 001__ 41821
000041821 003__ SzGeWIPO
000041821 005__ 20240708145800.0
000041821 008__ 200615s2020\\\\sz\\\\\\r\\\\\000\0\eng\d
000041821 022__ $$a1663-9812
000041821 040__ $$aSzGeWIPO$$beng$$erda
000041821 041__ $$aeng
000041821 1001_ $$aHeinrich, Michael
000041821 1001_ $$aScotti, Francesca
000041821 1001_ $$aAndrade-Cetto, Adolfo
000041821 1001_ $$aBerger-Gonzalez, Monica
000041821 1001_ $$aEcheverría, Javier
000041821 1001_ $$aFriso, Fabio
000041821 1001_ $$aGarcia-Cardona, Felipe
000041821 1001_ $$aHesketh, Alan
000041821 1001_ $$aHitziger, Martin
000041821 1001_ $$aMaake, Caroline
000041821 1001_ $$aPoliti, Matteo
000041821 1001_ $$aSpadafora, Carmenza
000041821 1001_ $$aSpadafora, Rita
000041821 24503 $$aAccess and Benefit Sharing Under the Nagoya Protocol—Quo Vadis?$$bSix Latin American Case Studies Assessing Opportunities and Risk
000041821 264_1 $$aLausanne, Switzerland :$$bFrontiers Media,$$c2020.
000041821 300__ $$a19 pages
000041821 336__ $$atext$$btxt$$2rdacontent
000041821 337__ $$aunmediated$$bn$$2rdamedia
000041821 338__ $$avolume$$bnc$$2rdacarrier
000041821 500__ $$aThis resource was extracted from the Directory of Open Access Journals (DOAJ)
000041821 520__ $$aGlobal challenges related to access and benefit sharing (ABS) of biological resources have become a key concern in the area of research on herbal medicines, ethnopharmacology, drug discovery, and the development of other high value products for which Intellectual Property protection can be secured. While the Convention on Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the implementation of the Nagoya Protocol (NP) and of new forms of collaboration often remain unresolved, especially in the context of “the fair and equitable sharing of benefits arising from the utilization of genetic resources” (Convention on Biological Diversity, 2011). The vision and the specific implementation of this international treaty vary from country to country, which poses additional challenges. Using a case study approach, in this analysis we aim at understanding the specific opportunities and challenges for implementing international collaborations regarding ABS in six Latin American countries—Chile, Colombia, Guatemala, México, Panama, and Peru. Based on that analysis, we provide recommendations for the path ahead regarding international collaborations under ABS agreements in ethnopharmacological research.
000041821 525__ $$aPublished in : Frontiers in Pharmacology, vol. 11 (2020)
000041821 650_0 $$aMedicine$$bTherapeutics
000041821 650_0 $$aPharmacology
000041821 85641 $$uhttps://doaj.org/article/41c2a43ea97b4b95bcca6ebe2ffc5e1b$$yView this resource
000041821 904__ $$aJournal article
000041821 980__ $$aBIB